KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Equivalents (2016 - 2025)

Sarepta Therapeutics has reported Cash & Equivalents over the past 16 years, most recently at $801.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 5.08% year-over-year to $801.3 million; the TTM value through Dec 2025 reached $801.3 million, down 5.08%, while the annual FY2025 figure was $801.3 million, 5.08% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $801.3 million at Sarepta Therapeutics, up from $613.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $2.1 billion in Q4 2021 and troughed at $197.9 million in Q3 2024.
  • A 5-year average of $904.3 million and a median of $848.1 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 63.49% in 2024 and later surged 209.87% in 2025.
  • Year by year, Cash & Equivalents stood at $2.1 billion in 2021, then crashed by 54.31% to $966.8 million in 2022, then plummeted by 55.68% to $428.4 million in 2023, then skyrocketed by 97.04% to $844.2 million in 2024, then fell by 5.08% to $801.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for SRPT at $801.3 million in Q4 2025, $613.1 million in Q3 2025, and $510.6 million in Q2 2025.